
Morphic Holding Investor Relations Material
Latest events

Study Update
Morphic Holding

Q1 2024
25 Apr, 2024

Q4 2023
22 Feb, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Morphic Holding Inc
Access all reports
Morphic Holding Inc., a biopharmaceutical company, specializes in the discovery and development of oral small-molecule integrin therapeutics. These treatments are aimed at addressing a variety of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. A key focus of their research is on MORF-057, an α4β7 integrin inhibitor designed to modulate inflammation, currently in clinical trials for treating inflammatory bowel disease. Morphic's pipeline also explores integrin targets for other gastrointestinal indications, myelofibrosis, and solid tumors among others. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the Nasdaq.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
MORF
Country
🇺🇸 United States